| 1 | 
                
                    IL17F
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | Bimekizumab 
                
                    Bimekizumab
                
             💬
 | 
                
                    Bimekizumab
                
             | [3]  46 46, 97, 271 💬
 | 
| 2 | 
                
                    IL31RA
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway | Nemolizumab 
                
                    Nemolizumab
                
             💬
 | 
                
                    Nemolizumab
                
             | [1]  51 51 💬
 | 
| 3 | 
                
                    IL17RA
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Alcoholic liver disease | Brodalumab 
                
                    Brodalumab
                
             💬
 | 
                
                    Brodalumab
                
             | [2]  37 37, 51 💬
 | 
| 4 | 
                
                    IDS
                
             💬
 | [3]  Glycosaminoglycan degradation Glycosaminoglycan degradation, Metabolic pathways, Lysosome | Idursulfase 
                
                    Idursulfase
                
             💬
 | 
                
                    Idursulfase
                
             | [1]  19 19 💬
 | 
| 5 | 
                
                    IDS
                
             💬
 | [3]  Glycosaminoglycan degradation Glycosaminoglycan degradation, Metabolic pathways, Lysosome | Idursulfase beta 
                
                    Idursulfase beta
                
             💬
 | 
                
                    Idursulfase beta
                
             | [1]  19 19 💬
 | 
| 6 | 
                
                    IDS
                
             💬
 | [3]  Glycosaminoglycan degradation Glycosaminoglycan degradation, Metabolic pathways, Lysosome | Pabinafusp alfa 
                
                    Pabinafusp alfa
                
             💬
 | 
                
                    Pabinafusp alfa
                
             | [1]  19 19 💬
 | 
| 7 | 
                
                    IDUA
                
             💬
 | [3]  Glycosaminoglycan degradation Glycosaminoglycan degradation, Metabolic pathways, Lysosome | Laronidase 
                
                    Laronidase
                
             💬
 | 
                
                    Laronidase
                
             | [2]  19 19, 256 💬
 | 
| 8 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 9 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 10 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 11 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 12 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 13 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 14 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 15 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 16 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 17 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 18 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 19 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 20 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 21 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 22 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 23 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 24 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 25 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 26 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 27 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 28 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 29 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 30 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 31 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 32 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 33 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 34 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2a 
                
                    Interferon alfa-2a
                
             💬
 | 
                
                    Interferon alfa-2a
                
             | [1]  56 56 💬
 | 
| 35 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1b 
                
                    Interferon beta-1b
                
             💬
 | 
                
                    Interferon beta-1b
                
             | [1]  13 13 💬
 | 
| 36 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2b 
                
                    Interferon alfa-2b
                
             💬
 | 
                
                    Interferon alfa-2b
                
             | [2]  25 25, 34 💬
 | 
| 37 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa 
                
                    Interferon alfa
                
             💬
 | 
                
                    Interferon alfa
                
             | [6]  13 13, 25, 26, 28, 56, 96 💬
 | 
| 38 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1a 
                
                    Interferon beta-1a
                
             💬
 | 
                
                    Interferon beta-1a
                
             | [4]  13 13, 26, 96, 97 💬
 | 
| 39 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Peginterferon beta-1a 
                
                    Peginterferon beta-1a
                
             💬
 | 
                
                    Peginterferon beta-1a
                
             | [1]  13 13 💬
 | 
| 40 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Anifrolumab 
                
                    Anifrolumab
                
             💬
 | 
                
                    Anifrolumab
                
             | [3]  46 46, 49, 53 💬
 | 
| 41 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2a 
                
                    Interferon alfa-2a
                
             💬
 | 
                
                    Interferon alfa-2a
                
             | [1]  56 56 💬
 | 
| 42 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1b 
                
                    Interferon beta-1b
                
             💬
 | 
                
                    Interferon beta-1b
                
             | [1]  13 13 💬
 | 
| 43 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2b 
                
                    Interferon alfa-2b
                
             💬
 | 
                
                    Interferon alfa-2b
                
             | [2]  25 25, 34 💬
 | 
| 44 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa 
                
                    Interferon alfa
                
             💬
 | 
                
                    Interferon alfa
                
             | [6]  13 13, 25, 26, 28, 56, 96 💬
 | 
| 45 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1a 
                
                    Interferon beta-1a
                
             💬
 | 
                
                    Interferon beta-1a
                
             | [4]  13 13, 26, 96, 97 💬
 | 
| 46 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Peginterferon beta-1a 
                
                    Peginterferon beta-1a
                
             💬
 | 
                
                    Peginterferon beta-1a
                
             | [1]  13 13 💬
 | 
| 47 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Anifrolumab 
                
                    Anifrolumab
                
             💬
 | 
                
                    Anifrolumab
                
             | [3]  46 46, 49, 53 💬
 | 
| 48 | 
                
                    IFNG
                
             💬
 | [32]  Proteasome Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Fontolizumab 
                
                    Fontolizumab
                
             💬
 | 
                
                    Fontolizumab
                
             | [1]  46 46 💬
 | 
| 49 | 
                
                    IFNG
                
             💬
 | [32]  Proteasome Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Emapalumab 
                
                    Emapalumab
                
             💬
 | 
                
                    Emapalumab
                
             | [3]  49 49, 65, 107 💬
 | 
| 50 | 
                
                    IFNGR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | Interferon gamma-1b 
                
                    Interferon gamma-1b
                
             💬
 | 
                
                    Interferon gamma-1b
                
             | [7]  18 18, 65, 85, 228, 299, 301, 326 💬
 | 
| 51 | 
                
                    IFNGR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | Interferon gamma-1b 
                
                    Interferon gamma-1b
                
             💬
 | 
                
                    Interferon gamma-1b
                
             | [7]  18 18, 65, 85, 228, 299, 301, 326 💬
 | 
| 52 | 
                
                    IGF1R
                
             💬
 | [29]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Oocyte meiosis, Autophagy - animal, Endocytosis, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Focal adhesion, Adherens junction, Signaling pathways regulating pluripotency of stem cells, Long-term depression, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Glioma, Prostate cancer, Melanoma, Breast cancer, Hepatocellular carcinoma | Mecasermin 
                
                    Mecasermin
                
             💬
 | 
                
                    Mecasermin
                
             | [6]  65 65, 78, 96, 168, 265, 299 💬
 | 
| 53 | 
                
                    IGF1R
                
             💬
 | [29]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Oocyte meiosis, Autophagy - animal, Endocytosis, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Focal adhesion, Adherens junction, Signaling pathways regulating pluripotency of stem cells, Long-term depression, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Glioma, Prostate cancer, Melanoma, Breast cancer, Hepatocellular carcinoma | Teprotumumab 
                
                    Teprotumumab
                
             💬
 | 
                
                    Teprotumumab
                
             | [1]  51 51 💬
 | 
| 54 | 
                
                    IGF1R
                
             💬
 | [29]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Oocyte meiosis, Autophagy - animal, Endocytosis, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Focal adhesion, Adherens junction, Signaling pathways regulating pluripotency of stem cells, Long-term depression, Ovarian steroidogenesis, Progesterone-mediated oocyte maturation, Pathways in cancer, Transcriptional misregulation in cancer, Proteoglycans in cancer, Glioma, Prostate cancer, Melanoma, Breast cancer, Hepatocellular carcinoma | Linsitinib 
                
                    Linsitinib
                
             💬
 | 
                
                    Linsitinib
                
             | [1]  232 232 💬
 | 
| 55 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 56 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Rilonacept 
                
                    Rilonacept
                
             💬
 | 
                
                    Rilonacept
                
             | [4]  51 51, 106, 107, 266 💬
 | 
| 57 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Bermekimab 
                
                    Bermekimab
                
             💬
 | 
                
                    Bermekimab
                
             | [1]  51 51 💬
 | 
| 58 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 59 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Rilonacept 
                
                    Rilonacept
                
             💬
 | 
                
                    Rilonacept
                
             | [4]  51 51, 106, 107, 266 💬
 | 
| 60 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Canakinumab 
                
                    Canakinumab
                
             💬
 | 
                
                    Canakinumab
                
             | [10]  46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
 | 
| 61 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Gevokizumab 
                
                    Gevokizumab
                
             💬
 | 
                
                    Gevokizumab
                
             | [4]  41 41, 50, 56, 269 💬
 | 
| 62 | 
                
                    IL1R1
                
             💬
 | [13]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis | Anakinra 
                
                    Anakinra
                
             💬
 | 
                
                    Anakinra
                
             | [18]  2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
 | 
| 63 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 64 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Basiliximab 
                
                    Basiliximab
                
             💬
 | 
                
                    Basiliximab
                
             | [6]  2 2, 50, 66, 97, 222, 228 💬
 | 
| 65 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Daclizumab 
                
                    Daclizumab
                
             💬
 | 
                
                    Daclizumab
                
             | [8]  13 13, 56, 60, 65, 97, 107, 283, 284 💬
 | 
| 66 | 
                
                    IL2RB
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 67 | 
                
                    IL2RG
                
             💬
 | [12]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 68 | 
                
                    IL4
                
             💬
 | [16]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Binetrakin 
                
                    Binetrakin
                
             💬
 | 
                
                    Binetrakin
                
             | [1]  46 46 💬
 | 
| 69 | 
                
                    IL4R
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | Dupilumab 
                
                    Dupilumab
                
             💬
 | 
                
                    Dupilumab
                
             | [5]  51 51, 97, 98, 160, 162 💬
 | 
| 70 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Mepolizumab 
                
                    Mepolizumab
                
             💬
 | 
                
                    Mepolizumab
                
             | [4]  44 44, 45, 98, 162 💬
 | 
| 71 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Reslizumab 
                
                    Reslizumab
                
             💬
 | 
                
                    Reslizumab
                
             | [2]  44 44, 98 💬
 | 
| 72 | 
                
                    IL5RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Benralizumab 
                
                    Benralizumab
                
             💬
 | 
                
                    Benralizumab
                
             | [5]  44 44, 45, 98, 162, 299 💬
 | 
| 73 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 74 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Pomalidomide 
                
                    Pomalidomide
                
             💬
 | 
                
                    Pomalidomide
                
             | [5]  28 28, 51, 85, 227, 331 💬
 | 
| 75 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Siltuximab 
                
                    Siltuximab
                
             💬
 | 
                
                    Siltuximab
                
             | [2]  28 28, 331 💬
 | 
| 76 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Sirukumab 
                
                    Sirukumab
                
             💬
 | 
                
                    Sirukumab
                
             | [2]  41 41, 46 💬
 | 
| 77 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Olokizumab 
                
                    Olokizumab
                
             💬
 | 
                
                    Olokizumab
                
             | [2]  46 46, 96 💬
 | 
| 78 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Tocilizumab 
                
                    Tocilizumab
                
             💬
 | 
                
                    Tocilizumab
                
             | [21]  2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
 | 
| 79 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Sarilumab 
                
                    Sarilumab
                
             💬
 | 
                
                    Sarilumab
                
             | [5]  41 41, 46, 84, 107, 271 💬
 | 
| 80 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Satralizumab 
                
                    Satralizumab
                
             💬
 | 
                
                    Satralizumab
                
             | [3]  11 11, 13, 86 💬
 | 
| 81 | 
                
                    IL10
                
             💬
 | [22]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 82 | 
                
                    IL11RA
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage | Oprelvekin 
                
                    Oprelvekin
                
             💬
 | 
                
                    Oprelvekin
                
             | [2]  96 96, 288 💬
 | 
| 83 | 
                
                    IL12A
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 84 | 
                
                    IL12B
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 85 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Anrukinzumab 
                
                    Anrukinzumab
                
             💬
 | 
                
                    Anrukinzumab
                
             | [1]  97 97 💬
 | 
| 86 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Lebrikizumab 
                
                    Lebrikizumab
                
             💬
 | 
                
                    Lebrikizumab
                
             | [1]  85 85 💬
 | 
| 87 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Tralokinumab 
                
                    Tralokinumab
                
             💬
 | 
                
                    Tralokinumab
                
             | [2]  85 85, 97 💬
 | 
| 88 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Secukinumab 
                
                    Secukinumab
                
             💬
 | 
                
                    Secukinumab
                
             | [8]  13 13, 37, 41, 46, 107, 160, 269, 271 💬
 | 
| 89 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Ixekizumab 
                
                    Ixekizumab
                
             💬
 | 
                
                    Ixekizumab
                
             | [8]  36 36, 37, 46, 107, 160, 162, 269, 271 💬
 | 
| 90 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Tibulizumab 
                
                    Tibulizumab
                
             💬
 | 
                
                    Tibulizumab
                
             | [1]  53 53 💬
 | 
| 91 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Bimekizumab 
                
                    Bimekizumab
                
             💬
 | 
                
                    Bimekizumab
                
             | [3]  46 46, 97, 271 💬
 | 
| 92 | 
                
                    IMPDH1
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mycophenolate mofetil 
                
                    Mycophenolate mofetil
                
             💬
 | 
                
                    Mycophenolate mofetil
                
             | [34]  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
 | 
| 93 | 
                
                    IMPDH1
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mizoribine 
                
                    Mizoribine
                
             💬
 | 
                
                    Mizoribine
                
             | [8]  46 46, 49, 51, 53, 66, 94, 222, 224 💬
 | 
| 94 | 
                
                    IMPDH1
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mycophenolic acid 
                
                    Mycophenolic acid
                
             💬
 | 
                
                    Mycophenolic acid
                
             | [36]  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
 | 
| 95 | 
                
                    IMPDH2
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mycophenolate mofetil 
                
                    Mycophenolate mofetil
                
             💬
 | 
                
                    Mycophenolate mofetil
                
             | [34]  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
 | 
| 96 | 
                
                    IMPDH2
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mizoribine 
                
                    Mizoribine
                
             💬
 | 
                
                    Mizoribine
                
             | [8]  46 46, 49, 51, 53, 66, 94, 222, 224 💬
 | 
| 97 | 
                
                    IMPDH2
                
             💬
 | [4]  Purine metabolism Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism | Mycophenolic acid 
                
                    Mycophenolic acid
                
             💬
 | 
                
                    Mycophenolic acid
                
             | [36]  2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
 | 
| 98 | 
                
                    INSR
                
             💬
 | [22]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Adherens junction, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy | Insulin human 
                
                    Insulin human
                
             💬
 | 
                
                    Insulin human
                
             | [2]  96 96, 156 💬
 | 
| 99 | 
                
                    INSR
                
             💬
 | [22]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Adherens junction, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy | Insulin glargine 
                
                    Insulin glargine
                
             💬
 | 
                
                    Insulin glargine
                
             | [1]  299 299 💬
 | 
| 100 | 
                
                    INSR
                
             💬
 | [22]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, cGMP-PKG signaling pathway, HIF-1 signaling pathway, FoxO signaling pathway, Phospholipase D signaling pathway, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Adherens junction, Insulin signaling pathway, Ovarian steroidogenesis, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy | Insulin detemir 
                
                    Insulin detemir
                
             💬
 | 
                
                    Insulin detemir
                
             | [1]  299 299 💬
 | 
| 101 | 
                
                    ITGA4
                
             💬
 | [14]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Firategrast 
                
                    Firategrast
                
             💬
 | 
                
                    Firategrast
                
             | [1]  13 13 💬
 | 
| 102 | 
                
                    ITGA4
                
             💬
 | [14]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Natalizumab 
                
                    Natalizumab
                
             💬
 | 
                
                    Natalizumab
                
             | [6]  13 13, 15, 25, 46, 63, 96 💬
 | 
| 103 | 
                
                    ITGA4
                
             💬
 | [14]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Vedolizumab 
                
                    Vedolizumab
                
             💬
 | 
                
                    Vedolizumab
                
             | [3]  94 94, 96, 97 💬
 | 
| 104 | 
                
                    ITGA4
                
             💬
 | [14]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Abrilumab 
                
                    Abrilumab
                
             💬
 | 
                
                    Abrilumab
                
             | [2]  96 96, 97 💬
 | 
| 105 | 
                
                    ITGAL
                
             💬
 | [12]  Rap1 signaling pathway Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis | Efalizumab 
                
                    Efalizumab
                
             💬
 | 
                
                    Efalizumab
                
             | [9]  11 11, 13, 37, 46, 49, 53, 61, 95, 96 💬
 | 
| 106 | 
                
                    ITGB7
                
             💬
 | [11]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Vedolizumab 
                
                    Vedolizumab
                
             💬
 | 
                
                    Vedolizumab
                
             | [3]  94 94, 96, 97 💬
 | 
| 107 | 
                
                    ITGB7
                
             💬
 | [11]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Etrolizumab 
                
                    Etrolizumab
                
             💬
 | 
                
                    Etrolizumab
                
             | [2]  96 96, 97 💬
 | 
| 108 | 
                
                    ITGB7
                
             💬
 | [11]  PI3K-Akt signaling pathway PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human papillomavirus infection, Transcriptional misregulation in cancer, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy | Abrilumab 
                
                    Abrilumab
                
             💬
 | 
                
                    Abrilumab
                
             | [2]  96 96, 97 💬
 | 
| 109 | 
                
                    IL20
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway | Fletikumab 
                
                    Fletikumab
                
             💬
 | 
                
                    Fletikumab
                
             | [1]  46 46 💬
 | 
| 110 | 
                
                    IL22
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | Efmarodocokin alfa 
                
                    Efmarodocokin alfa
                
             💬
 | 
                
                    Efmarodocokin alfa
                
             | [2]  96 96, 97 💬
 | 
| 111 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 112 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Tildrakizumab 
                
                    Tildrakizumab
                
             💬
 | 
                
                    Tildrakizumab
                
             | [2]  162 162, 271 💬
 | 
| 113 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Guselkumab 
                
                    Guselkumab
                
             💬
 | 
                
                    Guselkumab
                
             | [5]  37 37, 41, 51, 96, 97 💬
 | 
| 114 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Brazikumab 
                
                    Brazikumab
                
             💬
 | 
                
                    Brazikumab
                
             | [2]  96 96, 97 💬
 | 
| 115 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Risankizumab 
                
                    Risankizumab
                
             💬
 | 
                
                    Risankizumab
                
             | [4]  37 37, 96, 97, 271 💬
 | 
| 116 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Mirikizumab 
                
                    Mirikizumab
                
             💬
 | 
                
                    Mirikizumab
                
             | [3]  37 37, 96, 97 💬
 | 
| 117 | 
                
                    IL1R2
                
             💬
 | [7]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis | Anakinra 
                
                    Anakinra
                
             💬
 | 
                
                    Anakinra
                
             | [18]  2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
 | 
| 118 | 
                
                    IL1RL2
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Imsidolimab 
                
                    Imsidolimab
                
             💬
 | 
                
                    Imsidolimab
                
             | [1]  37 37 💬
 | 
| 119 | 
                
                    IL1RL2
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Spesolimab 
                
                    Spesolimab
                
             💬
 | 
                
                    Spesolimab
                
             | [3]  37 37, 96, 97 💬
 |